## AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. to 27. (Cancelled)

28. **(Currently Amended)** A method of treating a neoplastic disease in a patient in need thereof, wherein the neoplastic disease is selected from the group consisting of: carcinoma of the adrenal gland, carcinoma of the bladder, carcinoma of the breast, high grade glioma, glioblastoma multiforme, anaplastic astrocytoma, low grade astrocytoma, brain stem glioma, primitive neuroectodermal tumors, medulloblastoma, pinealoblastoma, rhabdoid tumor of the central nervous stystem, oligodendroglioma, mixed glioma, neurofibroma, schwannoma, visual pathway glioma, ependymoma, germ cell tumors, meningioma, carcinoma of the colon, carcinoma of the rectum, carcinoma of the esophagus, primary liver cancer, metastatic liver cancer, carcinoma of the head, carcinoma of the neck, adenocarcinoma of the lung, large cell undifferentiated carcinoma of the lung, bronchio-alveolar carcinoma of the lung, squamous cell carcinoma of the lung, nonsmall cell carcinoma of the lung, non-Hodgkin's lymphoma, chronic leukemia, mesothelioma, malignant melanoma, malignant fibrous histiocytoma, multiple myeloma, neuroblastoma, a neuroendocrine tumor, carcinoma of the ovary, carcinoma of the pancreas, a primitive neuroectodermal tumor outside the central nervous system, adenocarcinoma of the prostate, carcinoma of the kidney, sarcoma, carcinoma of the small intestine, carcinoma of the stomach, carcinoma of the uterus, carcinoma of the vulva, and carcinoma of an unknown primary source;

the method comprising:

administering to a patient at an infusion rate of from about 100 mL/hr to about 400 mL/hr of a pharmaceutical composition, the pharmaceutical composition comprising an aqueous solution of a compound of Formula IV:



wherein R and $R_1$ are independently selected from the group consisting of H, lower alkoxy ($C_{1-6}$), and lower alkyl ($C_{1-6}$); $R_2$ is selected from Formula II:



wherein X is a halogen, lower alkyl ($C_{1-6}$), lower alkoxy ($C_{1-6}$), cycloalkyl, cycloalkoxy, aryl, substituted aryl ($C_{6-12}$) or hydroxy and n is 0, 1, 2, 3, or 4; M is hydrogen, a salt forming cation, alkyl ($C_{1-6}$), cycloalkyl, or aryl ($C_{6-12}$); and n is 0-5; and,

a compound of Formula I:



or Formula III



wherein n is 0, 1, 2, 3, 4, or 5; M is hydrogen, a salt forming cation, an alkyl ($C_{1-6}$), a cycloalkyl, or an aryl ($C_{6-12}$); R and $R_1$ are independently selected from the group consisting of H, lower alkoxy ($C_{1-6}$), and lower alkyl ($C_{1-6}$); $R_2$ is selected from Formula II;

wherein the compound of Formula IV and the compound of Formula I or III are present in a 4:1 ratio by weight, and the combined concentration of the compound of Formula IV and the compound of Formula I or III is from about 70 mg/mL to about 150 mg/mL.

29. (Original) The method of claim 28, wherein the infusion rate is about 250 mL/hr to about 300 mL/hr, and further comprising performing the administering step sufficiently often to reach a dosage level of from about 0.1 g/kg/day to about 2.6 g/kg/day.

30. (Original) The method of claim 29, wherein the dosage level is from about 0.2 g/kg/day to about 0.9 g/kg/day.

31. to 47. (Cancelled)

48. **(Currently Amended)** The method of ~~[composition of]~~ claim 28, wherein in the compound of Formula IV, M is hydrogen or sodium; n is 0; R is H or $C_3H_7$; $R_1$ is selected from the group consisting of H, $CH_3$, $CH_3$-O-, $C_2H_5$, and $C_3H_7$; $R_2$ is selected from Formula II, wherein X is Cl, F, or OH; and wherein in the compound of Formula I or III, M is hydrogen or sodium; n is 0; R is H or $C_3H_7$; $R_1$ is selected from the group consisting of H, $CH_3$, $CH_3$-O-, $C_2H_5$, and $C_3H_7$; $R_2$ is selected from Formula II, wherein X is Cl, F, or OH.

49. **(Currently Amended)** The method of claim 28, wherein the compound of Formula IV is phenylacetic acid or a pharmaceutically acceptable salt ~~[salts]~~ thereof, and the compound of Formula I is phenylacetylglutamine or a pharmaceutically acceptable salt ~~[salts]~~ thereof, or the compound of Formula III is phenylacetylisoglutamine or a pharmaceutically acceptable salt ~~[salts]~~ thereof.

50. (Previously Presented) The method of claim 49, wherein the combined concentration of the compounds of formula IV and formula I or III is about 80 mg/mL.

51. **(Currently Amended)** The method of claim 28 wherein the pharmaceutical composition comprises a compound of formula I selected from phenylacetylglutamine or a pharmaceutically acceptable salt ~~[salts]~~ thereof.

52. **(Currently Amended)** The method of claim 28 wherein the pharmaceutical comprises a compound of formula III selected from phenylacetylisoglutamine or a pharmaceutically acceptable salt ~~[salts]~~ thereof.

53. **(Currently Amended)** The method of ~~[pharmaceutical composition of]~~ claim 28, wherein the compound of Formula IV and the compound of Formula I ~~[or III]~~ are present in a 4:1 ratio by weight.

--54. **(New)** The method of claim 28 wherein the compound of Formula IV and the compound of Formula III are present in a 4:1 ratio by weight.--